Pacira and Trius plunge into public markets in $1.3bn funding week for US biotech
This article was originally published in Scrip
Executive Summary
Eight public biotechnology companies floated stock offerings and note sales that grossed $1.3 billion in mid-January to keep their heads above water as they complete clinical trials, prepare regulatory filings or await drug approvals.